文献速递皮肤肿瘤皮肤感染

BRAF抑制剂相关皮肤鳞状细胞癌:病毒参与新机制与临床管理展望

BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management.
PubMed 文献 · Br J Dermatol · 2017-08-24

BRAF抑制剂(维莫非尼、达拉非尼)治疗转移性黑色素瘤常引发皮肤鳞状细胞癌(cSCC),机制尚不明确。本文综述其临床与分子特征,重点讨论病毒参与的证据,并为未来治疗干预提供新视角。

要点

  • BRAF抑制剂治疗转移性黑色素瘤常诱发cSCC,限制治疗持续性。
  • BRAF抑制剂诱导皮肤肿瘤的机制尚不明确,缺乏特异性防治手段。
  • 新兴证据提示病毒可能参与BRAF抑制剂相关cSCC的发生。

核心结论

  • BRAF抑制剂相关cSCC的发病机制尚不清楚,病毒参与的证据为新方向。
  • 持续临床与机制研究有望为接受靶向治疗的患者开发新的治疗与预防选择。

研究设计与样本

  • 本文为综述,总结BRAF抑制剂相关cSCC的临床与分子特征。

主要发现

  • BRAF抑制剂治疗转移性黑色素瘤常报告皮肤毒性,包括cSCC。
  • BRAF抑制剂诱导皮肤肿瘤的机制理解不足,构成特异性治疗挑战。
  • 新兴证据指向病毒参与BRAF抑制剂诱导的皮肤肿瘤。

关键数值与推荐

  • BRAF原癌基因突变见于大多数皮肤黑色素瘤。
  • 常见V600E突变驱动黑色素瘤发生,是维莫非尼和达拉非尼的靶点。

临床怎么用

  • 接受BRAF抑制剂治疗的患者需关注皮肤毒性及cSCC发生。
  • 病毒参与的证据提示未来可探索抗病毒或相关预防策略。

局限性

  • 本文为综述,未报告原始研究的具体样本量、效应值或统计显著性。
  • 病毒参与的证据尚属新兴,机制未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the BRAF proto-oncogene occur in the majority of cutaneous melanomas. The commonly detected valine (V) to glutamate (E) mutation (V600E) is known to drive melanomagenesis and has thus been the target of two highly selective chemotherapeutic agents: vemurafenib and dabrafenib. While BRAF inhibitor therapy has revolutionized the treatment of metastatic melanoma, unanticipated cutaneous toxicities, including the development of cutaneous squamous cell carcinomas (cSCCs), are frequently reported and hinder therapeutic durability. However, the mechanisms by which BRAF inhibitors induce cutaneous neoplasms are poorly understood, thus posing a challenge for specific therapies. In this review, we summarize the clinical and molecular profiles of BRAF inhibitor-associated cSCCs, with a focus on factors that may contribute to disease pathogenesis. In particular, we discuss the emerging evidence pointing towards viral involvement in BRAF inhibitor-induced cutaneous neoplasms and offer new perspectives on future therapeutic interventions. Continued clinical and mechanistic studies along this line will not only allow for better understanding of the pathogenic progression of BRAF inhibitor-induced cSCCs, but will also lead to development of new therapeutic and preventative options for patients receiving targeted cancer therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wu JH, Cohen DN, Rady PL, et al. BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol. 2017. PMID: 28129674. doi:10.1111/bjd.15348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。